Chen Schor

CIK: 0001340875

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (71.4%)

Compensation grants

Other (G, F, J, C, D, …)2 (28.6%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ACET

Adicet Bio, Inc.

DirectorOfficer

KPTI

Karyopharm Therapeutics Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (7 total)

ACET
Adicet Bio, Inc.
Jun 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
55K shares-
KPTI
Karyopharm Therapeutics Inc.
May 21, 2026
Award(A)
Direct
15.5K shares-
ACET
Adicet Bio, Inc.
Mar 25, 2026
Award(A)
Stock Option (Right to Buy)
Direct
468.6K shares-
ACET
Adicet Bio, Inc.
Jan 24, 2026
Tax Payment(F)
Direct
1.8K shares at avg. $8.44$15K
KPTI
Karyopharm Therapeutics Inc.
May 28, 2025
Award(A)
Nonstatutory Stock Option (right to buy)
Direct
4.6K shares-
ACET
Adicet Bio, Inc.
Jan 31, 2025
Award(A)
Stock Option (Right to Buy)
Direct
763.8K shares-
ACET
Adicet Bio, Inc.
Jan 24, 2025
Tax Payment(F)
Direct
28.1K shares at avg. $0.92$26K

		Type	Shares	Price		Ownership
Jun 19, 2026	ACET Adicet Bio, Inc.	Award(A) Stock Option (Right to Buy)	55,000	-	-	Direct
May 21, 2026	KPTI Karyopharm Therapeutics Inc.	Award(A)	15,508	-	$0	Direct
Mar 25, 2026	ACET Adicet Bio, Inc.	Award(A) Stock Option (Right to Buy)	468,555	-	-	Direct
Jan 24, 2026	ACET Adicet Bio, Inc.	Tax Payment(F)	1,755	$8.44	$14,812	Direct
May 28, 2025	KPTI Karyopharm Therapeutics Inc.	Award(A) Nonstatutory Stock Option (right to buy)	4,600	-	-	Direct
Jan 31, 2025	ACET Adicet Bio, Inc.	Award(A) Stock Option (Right to Buy)	763,829	-	-	Direct
Jan 24, 2025	ACET Adicet Bio, Inc.	Tax Payment(F)	28,101	$0.92	$25,904	Direct

1-7 of 7 transactions

About Schor Chen

Schor Chen (SEC CIK 0001340875) files insider reports with the SEC as President & CEO of Adicet Bio, Inc. (ACET) and Director of Karyopharm Therapeutics Inc. (KPTI).

Signal8 holds 7 ownership filings by Schor Chen, all Form 4s, filed between Jan 28, 2025 and Jun 23, 2026. Those filings report 7 transactions, from Jan 24, 2025 to Jun 19, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Schor Chen's filings is in BOSTON, MA.

Recent filings by Schor Chen

Jun 19, 2026: Grant or award of ACET derivative securities (Form 4, code A).
May 21, 2026: Grant or award of KPTI shares (Form 4, code A).
Mar 25, 2026: Grant or award of ACET derivative securities (Form 4, code A).
Jan 24, 2026: Tax withholding of ACET shares (Form 4, code F).
May 28, 2025: Grant or award of KPTI derivative securities (Form 4, code A).

Other insiders filing for Adicet Bio, Inc. (ACET)

Klickstein Lloyd, Chief Medical Officer
Aftab Blake, Chief Scientific Officer
DUBIN STEVE, Director
Chodakewitz Jeffrey, Director
Grissinger Michael, Director
Sinclair Andrew, Director

How to read Form 4 transaction codes